Sionna Therapeutics completes Phase 1 dosing for NBD1 stabilizers SION-719 and SION-451, with Phase 2a trials set for 2025. Sionna Therapeutics announced the completion of Phase 1 dosing for its NBD1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback